1. Home
  2. CLOV vs AGIO Comparison

CLOV vs AGIO Comparison

Compare CLOV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

N/A

Current Price

$4.24

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$33.03

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLOV
AGIO
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
CLOV
AGIO
Price
$4.24
$33.03
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$2.90
$38.88
AVG Volume (30 Days)
3.4M
785.4K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
38.03
N/A
EPS
0.10
N/A
Revenue
$1,924,308,000.00
$43,011,000.00
Revenue This Year
$52.59
$76.75
Revenue Next Year
$15.37
$170.73
P/E Ratio
$42.55
N/A
Revenue Growth
40.34
N/A
52 Week Low
$1.58
$22.24
52 Week High
$5.59
$46.00

Technical Indicators

Market Signals
Indicator
CLOV
AGIO
Relative Strength Index (RSI) 45.65 42.59
Support Level $4.09 $32.54
Resistance Level $4.23 $36.04
Average True Range (ATR) 0.13 1.11
MACD 0.01 0.00
Stochastic Oscillator 52.24 9.87

Price Performance

Historical Comparison
CLOV
AGIO

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: